Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis: an open-label comparative trial versus standard of care treatments

Background Distal renal tubular acidosis (dRTA), due to impaired acid secretion in the urine, can lead to severe long-term consequences. Standard of care (SoC) oral alkalizers, requiring several daily intakes, are currently used to restore normal plasma bicarbonate levels. A new prolonged-release fo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric nephrology (Berlin, West) West), 2021-01, Vol.36 (1), p.83-91
Hauptverfasser: Bertholet-Thomas, Aurélia, Guittet, Catherine, Manso-Silván, Maria A., Castang, Arnaud, Baudouin, Véronique, Cailliez, Mathilde, Di Maio, Massimo, Gillion-Boyer, Olivia, Golubovic, Emilija, Harambat, Jérôme, Klein, Alexandre, Knebelmann, Bertrand, Nobili, François, Novo, Robert, Podracka, Ludmila, Roussey-Kesler, Gwenaëlle, Stylianou, Christos, Granier, Luc-André
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Distal renal tubular acidosis (dRTA), due to impaired acid secretion in the urine, can lead to severe long-term consequences. Standard of care (SoC) oral alkalizers, requiring several daily intakes, are currently used to restore normal plasma bicarbonate levels. A new prolonged-release formulation, ADV7103, has been developed to achieve a sustained effect with an improved dosing scheme. Methods In a multicenter, open-label, non-inferiority trial ( n  = 37), patients with dRTA were switched from SoC to ADV7103. Mean plasma bicarbonate values and proportion of responders during steady state therapy with both treatments were compared, as were other blood and urine parameters, as well as acceptability, tolerability, and safety. Results When switching from SoC to ADV7103, the number of daily intakes was reduced from a median of three to twice daily. Mean plasma bicarbonate was increased and non-inferiority of ADV7103 was demonstrated ( p  
ISSN:0931-041X
1432-198X
DOI:10.1007/s00467-020-04693-2